We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Biomarker Development Strategies

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biomarker Development Strategies "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

ExL Pharma have announced that their Biomarker Development Strategies conference will be held at the Omni Shoreham Hotel in
Washington, DC, January 29-30, 2007

• Hear directly from the FDA about the new regulatory framework for biomarkers

• Hear case studies and real world examples from Novartis, Eli Lilly, Amgen, Bristol Myer
Squibb, Centocor/J&J, Wyeth and National Cancer Institute

• Discover the Role of Collaborations & Consortia in Biomarker advancement

• Advances in the use of Proteomics, Metabolomics and Nanotechnology for Biomarker-
Based Drug Development

• Applications of Biomarkers in Early Phase Studies

• Using Biomarkers for Oncology Clinical Development

Faculty includes: 
Alfred Ajami, CSO, Xanthus Pharmceuticals
Felix Frueh, Associate Director Genomics, FDA
Michael Shi, Director of Biomarker Development, Novartis

Register Today! Call 866-207-6529 or visit us at www.exlpharma.com